Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyr3 is a selective small molecule inhibitor of the canonical transient receptor potential channel 3 (**TRPC3**), used primarily in research settings to block TRPC3-mediated calcium influx (IC50 ~0.7 μM), resulting in inhibition of downstream calcium-dependent signaling pathways. It suppresses activation of nuclear factor of activated T cells (NFAT) and inhibits hypertrophic responses in cardiomyocytes. Pyr3 is not an approved pharmaceutical; it is most commonly applied in cardiovascular, neuronal, and smooth muscle cell biology studies to dissect TRPC3 function[1][2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pyr3.